Figure S1
**Fig. S1. Discovery of coldspot antibodies.** (A) Cartoon diagram of the SARS-CoV-2 S with highlighted coldspot regions at the fusion peptide (FP, red) and near heptad repeat 2 (HR2, blue), as well as subdomain 1 (SD1, green). The thick horizontal lines underneath indicate the location of all coldspots, and the histograms show the frequency of aa changes throughout S at different time points: 31.12.2020 (671,006), 31.12.2021 (7,526,116) and 29.04.2022 (10,480,461 sequences from GISAID). (B) ELISA reactivity of plasma IgG antibodies to FP (top) and HR2 (middle) peptides or to SARS-CoV-2 RBD (bottom). SARS-CoV-2 (n=67) and common cold CoV (n=6) convalescent samples are compared to COVID-19 vaccinees (mRNA: BNT162b2 n=11, purple; mRNA-1273 n=5, pink; inactivated virus: Sinovac n=2, dark green; Sinopharm n=24, light green; adenovirus: ChAdOx1-S n=19, orange; Ad26.COV2.S n=4, yellow), and to non-infected controls (n=25). Area Under the Curve (AUC); average of two experiments. The percentage of samples with antibody levels 4 standard deviations above controls is shown on top. (C) Gating strategy for sorting peptide-specific or SD1-enriched B cells by flow cytometry. (D) Identification of FP-peptide specific (top) and HR2-peptide specific (bottom) B cells by flow cytometry. Numbers indicate percentage of gated double-positive cells. (E) Clonal analysis of antibody sequences derived from peptide-specific B cells identified in (D). Pie charts show the total number of antibody sequences (center); the size of the slices is proportional to the number of clonally related sequences. White slices indicate antibody sequences that are not part of a clone.
Fig. S2. Similarity of peptides at the FP and HR2 of Orthocoronavirinae. (A) Phylogenetic analysis of CoV species based on the aa sequence of S. (B) Alignment of SARS-CoV-2 FP and HR2 peptide sequences with those corresponding to related CoVs. In green identical residues; in yellow residues that are similar by side chain functionality.
Fig. S3. Broadly crossreactive binding of FP and HR2 monoclonal antibodies. (A and B) Graphs show ELISAs measuring monoclonal antibodies reactivity to S (A) and to coldspot peptides (B) of coronaviruses. Mean of two independent experiments.
Figure S4

**Fig. S4.** Broad neutralization by FP and HR2 monoclonal antibodies. (A and B) Neutralization of ancestral SARS-CoV-2 pseudovirus. Graphs show normalized relative luminescence values in cell lysates of 293TACE2 (A) or 293TACE2/TMPRSS2 (B) cells 48 hours after infection with nanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasing concentrations of monoclonal antibodies to the FP (top) and HR2 (bottom). Isotype control and antibodies C135 (4), CV3-25 and S2P6 were assayed alongside for comparison; additional antibodies in grey (table S2). Mean of at least two independent experiments. (C) Same as in (A), but for SARS-CoV-2 pseudoviruses corresponding to VOC. (D) Neutralization of SARS-CoV-2 ancestral and Omicron BA.1 by Focus Reduction Neutralization Test (FRNT).
Figure S5

| A                              | heavy chain | light chain |
|-------------------------------|-------------|-------------|
| CDRH1                         | 31 52 52A 53 55 56 57 58 87 98 99 100A 100F | F 93 94 95 95A |
| p.006Residue                  | N S Y E R N K K F L S Y Y E D W P L         |
| BSA (A F)                     | 13 13 13 13 13 46 46 69 3 46 18 67 2 77 84 | 14 12 12 76 49 21 |

| B                              | fusion peptide |
|-------------------------------|----------------|
| Residue Number               | 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 |
| Conservation (%)              | 22 14 82 109 18 78 94 100 66 98 86 37 92 32 12 14 18 29 |
| FP Residue                    | S K R G F I E D L N K V T L A D |
| BSA (A F)                     | 6 22 172 46 0 57 67 48 0 89 175 3 71 0 0 22 0 0 |

| C                              | D                          |
|--------------------------------|-----------------------------|
| FRL1                           | hydrophilic face            |
| CDRH2                          | hydrophobic face            |
| CDRH1                          |                             |
| CDRH3                          |                             |

| E                              | G                          |
|--------------------------------|-----------------------------|
| EB19                           | fusion peptide             |
| E816                           |                             |
| P823                           |                             |
| CDRH2                          |                             |
| CDRH1                          |                             |
| CDRH3                          |                             |

| H                              | I                          |
|--------------------------------|-----------------------------|
| 0 50K 100K 150K 200K 250K     | 0 10^2 10^4 10^6 10^8 |
| FSC-A                         | mAb-DV.847P1               |
| SSC-A                         |                             |
| 0 250K                         |                             |
|                               |                             |
|                               |                             |
| 0.1 0.5 1.0 1.5 2.0 2.5       | 10^-10 10^-5 10^-1 10^0 10^1 10^2 |
|                               |                             |

bioRxiv preprint doi: https://doi.org/10.1101/2022.11.24.515932; this version posted November 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Fig. S5. Structure of fp.006 in complex with peptide antigen and effects of ACE2 engagement. (A) Contributions of fp.006 heavy and light chain paratope residues to the binding of the fusion peptide. Residue number, identity, and buried surface area (BSA) are shown, and colored as in panel (C). (B) Per residue contributions of the FP to the fp.006 epitope. Conservation calculated from the 49 CoV sequences listed in fig. S2B and BSA calculations per FP residue are listed. *Indicates that the BSA calculation does not include contacts mediated by water molecules. (C) Surface representation of the fp.006 paratope with interacting residues colored according to their CDR loop identity. Non-interacting heavy chain and light chain residues are colored teal and light teal, respectively. (D) Surface representation of the fp.006 paratope with per residue lipophilicity calculations shown. More hydrophobic patches are colored orange and more hydrophilic patches are colored teal, as calculated by ChimeraX. (E) Representative electron density for a portion of the FP contoured at 1.7σ. (F) Overlay of complex structures between the SARS-CoV-2 fusion peptide and fp.006 (this study; PDB 8D47), VN01H1 (PDB 7SKZ), and COV91-27 (PDB 8D6Z) illustrates a convergent binding mode independent of V gene usage. Structures are aligned on their fusion peptide chains and colored as shown. (G) Overlay of complex structures between the SARS-CoV-2 fusion peptide and fp.006 (this study; PDB 8D47), COV44-62 (PDB 8D36), and 76E1 (PDB 7X9E) Fabs, illustrating that anti-FP mAbs of different poses bind to the same face of the amphipathic fusion peptide α-helix, which includes highly-conserved residues, which are shown as sticks. (H) Gating strategy for measuring the binding of monoclonal antibodies to the SARS-CoV-2 S expressed by 293T cells by flow cytometry. (I) Normalized relative luminescence values in cell lysates of 293TACE2 cells after infection with ancestral SARS-CoV-2 pseudovirus in the presence of increasing concentrations of FP or HR2 antibodies alone or as a cocktail with soluble ACE2. Isotype control in black. For the combination of fp.006+ACE2, P=0.0017 over fp.006 and P=0.0047 over ACE2; for the combination of fp.007+ACE2, P=0.0072 over fp.007 and P=0.2 over ACE2 (n=4; Welch’s t-test, two-tailed).
**Fig. S6. Discovery of SD1 and RBD antibodies.** (A) Graph shows ELISAs measuring plasma IgG reactivity to RBD. Negative controls in black. Mean of two independent experiments. (B) Correlation of plasma IgG reactivities to SD1-RBD and RBD. Pearson correlation. (C) Identification of SD1-enriched B cells by flow cytometry. (D and E) Graphs show ELISAs measuring monoclonal antibodies reactivity to SD1-RBD (D) and S (E) corresponding to SARS-CoV-2 VOC. Mean of two independent experiments. (F) Heatmaps with the binding (EC$_{50}$) of RBD monoclonal antibodies to S (top) or SD1-RBD (bottom) proteins corresponding to SARS-CoV-2 VOC. Two experiments. (G) Graphs and summary heatmap for SD1 antibodies binding to SD1-RBD mutant proteins T572I and E583D. (H) Neutralization of ancestral SARS-CoV-2 pseudovirus by antibodies to the RBD that are broadly crossreactive to VOC.
Figure S7

(A) Image showing 100 nm scale bar.

(B) Diagram with various representations of molecular structures.

(C) Graph showing resolution against structure factor.

(D) Heatmap illustrating local resolution.

(E) Image showing NTD, RBD, and sd1.040 binding sites.

(F) Image showing P008_60, P008_60_Lc, S3H3_Lc, and S3H3_HC binding sites.

(G) Image showing NTD and sd1.040 bound.

(H) Image showing NTD spike trimer and sd1.040 bound.
**Fig. S7. Structure of sd1.040 in complex with S.** (A) Representative micrograph and 2D class averages selected from the sd1.040-S dataset. (B) 3D classification workflow and final refinement strategy. (C) Gold-standard FSC plot for the final cryo-EM density map. (D) Local resolution estimates calculated in cryoSPARC v3.1. (E) Close-up view of the sd1.040 Fab – S complex superimposed onto a prefusion S trimer (PDB 6VXX). Potential clashes with the NTD (cyan) on the neighboring S1 protomer are denoted by a red star. (F) Close-up views of the P008_60 Fab (PDB 7ZBU) and S3H3 Fab (PDB 7WD9) superposed onto a prefusion trimeric Spike. Antibody P008_60 shows prominent clashes with the adjacent NTD (red star), while the binding orientation of S3H3 does not clash with neighboring protomers. (G and H) According to docking simulations, sd1.040 binds also to the NTD of the adjacent protomer. In (G), NTD moves from the position observed in the experimental structure of the free S to make room for antibody binding (sd1.040 in dark green bound to NTD in purple). In (H), comparison between NTD bound to sd1.040 in simulations (purple) and NTD in the context of free spike trimer (lime).
Fig. S8. Binding and neutralizing properties of CoV-X4042. (A) Both arms of CoV-X4042 bind simultaneously to the same SD1-RBD molecule. Left, diagram showing that at high SD1-RBD concentrations, monoclonal antibodies have avidity effects owing to intermolecular binding (which results in a slower kd), but this is not the case at low SD1-RBD concentrations, because bivalent binding to a single SD1-RBD is impossible. By contrast, the bispecific antibody has avidity at both high and low concentrations, since bivalent binding to its two epitopes on a single SD1-RBD is possible. ka is not affected by avidity. Right, table summarizing the SPR results used to determine ka and kd of IgG, Fab and the bispecific antibody at different concentrations of immobilized SD1-RBD, which confirm experimentally that CoV-X4042 engages bivalently on a single SD1-RBD. (B) Neutralization of VOC by CoV-X4042 and parental monoclonal antibodies.